Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23582774 | 0.84 | MAPT (0.43) | MAPTKMT2AALOX5AOC3LMNA | |
| SCHEMBL17520105 | 0.84 | MAPT (0.46) | MAPTKMT2AALOX5AOC3EPHX1 | |
| SCHEMBL8314829 | 0.79 | MAPT (0.48) | MAPTKMT2AALOX5AOC3ADRA2A | |
| SCHEMBL6017678 | 0.77 | MAPT (0.50) | MAPTKMT2AALOX5AOC3EPHX1 | |
| SCHEMBL11663964 | 0.72 | L3MBTL1 (0.45) | KMT2AAOC3LMNATDP1L3MBTL1 | |
| SCHEMBL17223814 | 0.71 | KMT2A (0.44) | MAPTKMT2AALOX5AOC3LMNA | |
| SCHEMBL7475015 | 0.71 | ALOX5 (0.55) | ALOX5EPHX1ADRA2AADRA2CLMNA | |
| SCHEMBL28260719 | 0.71 | ALOX5 (0.55) | ALOX5EPHX1ADRA2AADRA2CLMNA | |
| SCHEMBL341787 | 0.71 | ALOX5 (0.50) | ALOX5EPHX1ADRA2AADRA2CLMNA | |
| SCHEMBL14246913 | 0.70 | KMT2A (0.47) | MAPTKMT2AALOX5ADRA2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | MAPT 1533/4885KMT2A 58/4885ALOX5 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.